HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 2,797-2,808 of 4,505
Other study type icon
TerminatedNCT01894984

Risperidone Long-Acting Injection for schizophrenia

Official study title

Clinical Observation of the Efficacy and Safety of Risperidone Long-Acting Injection (Risperdal Consta) in the Treatment of Schizophrenia in China

This study ended early.

Location not clearly listed
SchizophreniaObservational studyAges 18–65
Countries
Sponsor
Xian-Janssen Pharmaceutical Ltd.
Drug study icon
CompletedNCT00473434

Paliperidone doses after switching from another antipsychotic

About this title

An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia

Read the official source — NCT00473434
Official study title

An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
Janssen-Cilag Pty Ltd
Drug study icon
CompletedNCT01646827

Aripiprazole Injection in the Shoulder or Buttock

About this title

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

Read the official source — NCT01646827
Official study title

An Open-label, Randomized, Parallel Arm, Bioavailability Trial of Aripiprazole IM Depot Administered in the Deltoid or Gluteal Muscle in Adult Subjects With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Cerritos
SchizophreniaMedication studyAges 18–64
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT00246272

Rapid-dissolving risperidone tablets after switching from regular tablets

About this title

An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone

Read the official source — NCT00246272
Official study title

An Open-label Study Evaluating the Maintenance of Clinical Effect in Adults With Schizophrenia Switched From RISPERDAL® Tablets (Risperidone) to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18+
Countries
Sponsor
Janssen-Ortho Inc., Canada
Drug study icon
CompletedNCT02320032

An Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Official study title

A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Alkermes, Inc.
Drug study icon
TerminatedNCT01939548

Efficacy, Safety, And Tolerability Of PF-02545920 for schizophrenia

Official study title

A 12-week , Randomized, Phase 2, Double-blind, Parallel-group Study Of Two Dose Levels Of Pf-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-optimally Controlled Symptoms Of Schizophrenia

This study ended early.

Multiple locations, including Birmingham
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Pfizer
Drug study icon
CompletedNCT00417482

Stopping antipsychotic treatment after improvement in Alzheimer-related agitation or psychosis

About this title

Antipsychotic Discontinuation in Alzheimer's Disease

Read the official source — NCT00417482
Official study title

Antipsychotic Discontinuation in Alzheimer's Disease

This study has finished and is no longer accepting participants.

Multiple locations, including Tuscaloosa
SchizophreniaMedication studyAges 50–95
Countries
United States
Sponsor
New York State Psychiatric Institute
Device study icon
WithdrawnNCT01979796

Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning.

Official study title

Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning: Design of a Randomized Trial. Smoking Cessation And Reduction In Schizophrenia (The SCARIS Study)

This study was withdrawn before enrollment.

Location not clearly listed
SchizophreniaDevice studyAges 18–65
Countries
Sponsor
University of Catania
Drug study icon
CompletedNCT03287505

Aripiprazole IM Depot for Chinese people with Schizophrenia

What is this study about?

This study evaluated the safety of Aripiprazole IM Depot for people with schizophrenia.

This study has finished and is no longer accepting participants.

In Beijing
SchizophreniaMedication studyAges 18–64
Countries
China
Sponsor
Otsuka Beijing Research Institute
Drug study icon
CompletedNCT03172871

Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia

Official study title

A Multicenter, Randomized, Double-blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Aripiprazole Intramuscular Depot in the Acute Treatment of Adults With Schizophrenia

This study has finished and is no longer accepting participants.

In Beijing
SchizophreniaMedication studyAges 18–65
Countries
China
Sponsor
Otsuka Beijing Research Institute
Drug study icon
CompletedNCT00095810

Aripiprazole safety for psychosis in Parkinson’s disease

About this title

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

Read the official source — NCT00095810
Official study title

An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease

This study has finished and is no longer accepting participants.

In Albany
SchizophreniaMedication studyAges 50+
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT01438060

Aripiprazole or Placebo for Psychosis in Alzheimer’s Disease

About this title

Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type

Read the official source — NCT01438060
Official study title

A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 55–95
Countries
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.